Jarushka Naidoo
Medical Oncology · New York, NYNPI 1710327721
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $99,390 of the $112,152 with a category attached, or 88.6%. 12 manufacturers reported payments, led by AstraZeneca at 37.7% of the total. Reporting peaked in 2021 at $33,024 and has fallen 97.0% since, to $1,000 in 2025.
Across 80 payments — averaging $1401.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$42K
- Daiichi Sankyo Inc.$29K
- E.r. Squibb & Sons, L.L.C.$17K
- Astrazeneca UK Limited$13K
- Merck$6K
- F. Hoffmann-la Roche AG$2K
- plus $4K from 6 others
Across 503 payments — averaging $3016.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1M
- Merck$337K
- Incyte Corporation$140K
- Astrazeneca UK Limited$21K
What the payments were for
- Consulting fees$99,39089%
- Travel & lodging$5,1735%
- Food & beverage$1,4461%
- Education$6,1435%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $42,306 |
| Daiichi Sankyo Inc. | 22 | $28,789 |
| E.r. Squibb & Sons, L.L.C. | 12 | $16,967 |
| Astrazeneca UK Limited | 6 | $13,015 |
| Merck | 2 | $5,500 |
| F. Hoffmann-la Roche AG | 3 | $1,887 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $1,533 |
| Genentech, Inc. | 3 | $874 |
| Gilead | 1 | $862 |
| Genentech USA, Inc. | 3 | $232 |
| Regeneron | 2 | $126 |
| AbbVie | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,152 in reported general payments places this provider in the 85th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.